BioXcel Therapeutics (BTAI) gained 3% premarket after its drug BXCL501 demonstrated continued efficacy and safety in a late-stage trial for agitation related to bipolar disorder and schizophrenia. The orally dissolving film formulation showed consistent benefits with repeat dosing, enhancing its potential for outpatient use.